Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 11:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 1,549 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ulcers Clear all
Terminated Phase 2Phase 3 Interventional Results available

Immunonutrition for Diabetic Foot Ulcers

NCT05281562
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Peripheral Neuropathy, Diabetic Foot Ulcer
Interventions
Lovaza, L-Arginine Powder, Vitamin C
Drug
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 27, 2026, 11:14 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis

NCT01016262
View directory record Official record
Conditions
Proctitis, Ulcerative
Interventions
MAX-002, Placebo, Canasa®
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 27, 2026, 11:14 PM EDT
Withdrawn Phase 1 Interventional

Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease

NCT03414788
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
PF 06687234, [124I]IB PF 06687234
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

NCT04469686
View directory record Official record
Conditions
Ulcerative Proctitis
Interventions
Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Twice daily placebo suppository administered with Sephure applicator
Combination Product
Lead sponsor
Cristcot HCA LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
51
States / cities
Huntsville, Alabama • Apple Valley, California • Camarillo, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

NCT01737762
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
HP802-247, Vehicle
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
37
States / cities
Phoenix, Arizona • Carlsbad, California • Castro Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Phase 2 Interventional

Intra-oral Treatment of OLP With Rivelin®-CLO Patches

NCT03592342
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
Clobetasol Propionate
Drug
Lead sponsor
Dermtreat
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Hialeah, Florida • Miami, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 27, 2026, 11:14 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

NCT07113522
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
Interventions
MT-501, MT-201
Drug
Lead sponsor
Mirador Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sun City, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional

Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients

NCT03972527
View directory record Official record
Conditions
Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation, Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Head and Neck Cancer
Interventions
Photobiomodulation, Routine Oral Care and Analgesia
Device · Other
Lead sponsor
MuReva Phototherapy Inc.
Industry
Eligibility
22 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Long Beach, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional Results available

Characterization of AmnioExcel Plus in Two Treatment Paradigms

NCT04233580
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Amnio Excel + weekly, Amnio Excel + max every 2 weeks
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 27, 2026, 11:14 PM EDT
Terminated Phase 2 Interventional Results available

Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury

NCT01433159
View directory record Official record
Conditions
Pressure Ulcers, Spinal Cord Injury
Interventions
HP011-101 (Xenaderm Ointment), Standard Care
Drug
Lead sponsor
Healthpoint
Industry
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Long Beach, California • San Jose, California • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Phase 1Phase 2 Interventional

Morphine Gel for Bedsores

NCT00007254
View directory record Official record
Conditions
Decubitus Ulcer
Interventions
Pain relief for pressure ulcers
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 27, 2026, 11:14 PM EDT
Terminated Phase 4 Interventional Results available

An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

NCT05369832
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Ozanimod
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
85
States / cities
Dothan, Alabama • Chandler, Arizona • Gilbert, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 27, 2026, 11:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dysmenorrhea in Women With Crohn's Disease and Ulcerative Colitis

NCT02274714
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Questionnaire Only
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 27, 2026, 11:14 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

NCT02520284
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Andecaliximab, Placebo
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
33
States / cities
Dothan, Alabama • Wheat Ridge, Colorado • Lauderdale Lakes, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional

Microbiota-targeted Diet for Pediatric UC

NCT02922881
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ulcerative Colitis Diet (UCD)
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 19 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 27, 2026, 11:14 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

NCT07071519
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
12
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 11:14 PM EDT
Terminated Phase 2 Interventional

Prevention of Infection Using a Topical Gentamicin-Collagen Sponge in Diabetic Patients With An Uninfected Foot Ulcer

NCT00658957
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
gentamicin-collagen sponge, placebo collagen sponge
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pasadena, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 27, 2026, 11:14 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

NCT05731128
View directory record Official record
Conditions
Colitis Ulcerative
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Apple Valley, California • Beverly Hills, California • Oxnard, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 27, 2026, 11:14 PM EDT
Completed No phase listed Observational

Multi-center Acute Severe Ulcerative Colitis Cohort Study (MASCC)

NCT03669822
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Standard of care
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 27, 2026, 11:14 PM EDT
Completed No phase listed Observational

Pharmacist-Driven Stress Ulcer Prophylaxis Minimization in the Intensive Care Unit

NCT06225167
View directory record Official record
Conditions
Stress Ulcer
Interventions
To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.
Behavioral
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 27, 2026, 11:14 PM EDT
Terminated Not applicable Interventional

Health Economic Assessment of Lower Extremity Diabetic (HEALED) Ulcers With PriMatrix

NCT01729286
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
PriMatrix Moist Wound Therapy, Standard of Care Moist Wound Therapy
Device · Other
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
15
States / cities
Los Angeles, California • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 27, 2026, 11:14 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Gene Expression in Inflammatory Bowel Disease

NCT01171872
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
7 Years and older
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2032
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional

Pilot Study of PHOENIX Wound Matrix® Impact on Chronic DFU Wound Microbiome

NCT04437537
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Bioresorbable 3D electrospun synthetic matrix
Device
Lead sponsor
RenovoDerm
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Northampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 27, 2026, 11:14 PM EDT
Completed No phase listed Observational

Identify Predictors That Distinguish Between Tofacitinib Responders and Non-responders Based on Genotype and Cellular and Molecular Profiles From Pinch Biopsies, Blood and Stool Samples

NCT03663400
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
GWAS analysis by Illumina BeadChip
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 27, 2026, 11:14 PM EDT